ASCO 2020: BCMA CAR-T Race Heats Up Between Bristol And Janssen

 
• By Mandy Jackson

The gap between potential approvals for Bristol’s ide-cel and Janssen’s JNJ-4528 has narrowed as both CAR-T therapies show high response rates in multiple myeloma – and as bispecific antibodies, including Janssen’s teclistamab, edge into the space.

T cell lymphocyte with receptors to kill cancer cell in cancer immunotherapy 3D render
CAR-T cells targeting BCMA induce high responses in heavily pre-treated myeloma • Source: Shutterstock

More from ASCO

More from Conferences